About
Intranasal Innate Immune Enhancers
Boosting local innate immunity to stop respiratory viral infections in their tracks
ENA Respiratory is a clinical-stage pharmaceutical company. We are tackling the resulting serious complications (sequelae) of respiratory viral infections through the development of host defence immune enhancers which locally prime and boost the body’s innate immune response – the natural first line of defence.
The company’s immune enhancers have been shown in preclinical and clinical studies to be effective against a diverse range of respiratory viruses, including SARS-CoV2, rhinovirus, H1N1, and seasonal influenza strains. They complement vaccine and direct-acting antiviral approaches, which are most often virus specific.
